About: Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus
Creator	Kim, Hyun Chang Id, Jun Kim, Myung
Source	Medline; PMC
abstract	Middle East respiratory syndrome coronavirus (MERS-CoV) causes an acute and severe lower respiratory illness as well as vomiting, diarrhea, and renal failure. Because no licensed MERS-CoV vaccines are currently available, preventive and therapeutic measures are urgently needed. The surface spike (S) glycoprotein of MERS-CoV, which binds to the cellular receptor dipeptidyl peptidase 4 (DPP4), is considered as a major target for MERS-CoV vaccine development. Here, we designed recombinant replication-deficient adenovirus-based vaccines expressing the N-terminal domain (rAd/NTD) and receptor-binding domain (rAd/RBD) of the MERS-CoV S1 subunit and full-length Spike protein (rAd/Spike). We found that immunization with candidate vaccines via intranasal route induced S1-specific IgG antibodies and neutralizing antibodies against MERS spike pseudotyped virus. Especially, rAd/Spike induced the highest neutralizing antibody titer and the strongest cytokine-induced T cell responses among the three candidate vaccines. To compare the immune responses induced by different administration routes, rAd/Spike was administered via intranasal, sublingual, or intramuscular route. All these administration routes exhibited neutralizing effects in the serum. MERS-CoV-specific neutralizing IgA antibodies in the bronchoalveolar lavage fluid were only induced by intranasal and sublingual administration but not by intramuscular administration. Intranasal administration with rAd/Spike also created resident memory CD8 T cells in the airway and lung parenchyma. Taken together, our results showed that both the humoral and cellular immune responses are highly induced by rAd/Spike administration, suggesting that rAd/Spike may confer protection against MERS-CoV infection.
has issue date	2019-07-22(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0220196
bibo:pmid	31329652
has license	cc-by
sha1sum (hex)	7aaffdb8cf80ab9dd167a26a44abfa21d30d2af5
schema:url	https://doi.org/10.1371/journal.pone.0220196
resource representing a document's title	Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus
has PubMed Central identifier	PMC6645677
has PubMed identifier	31329652
schema:publication	PLoS One
resource representing a document's body	covid:7aaffdb8cf80ab9dd167a26a44abfa21d30d2af5#body_text
is schema:about of	named entity 'vaccine' named entity 'memory' named entity 'lung parenchyma' named entity 'ACCESS' named entity 'expressing' named entity 'Because' named entity 'neutralizing antibody' named entity 'vaccines' named entity 'coronavirus' named entity 'immunization' named entity 'Spike' named entity 'immune responses' covid:arg/7aaffdb8cf80ab9dd167a26a44abfa21d30d2af5 named entity 'major' named entity 'protein' named entity 'intramuscular' named entity 'licensed' named entity 'compare' named entity 'protein' named entity 'created' named entity 'administration' named entity 'immunization' named entity 'antibody titer' named entity 'Spike' named entity 'immune responses' named entity 'vomiting' named entity 'sublingual' named entity 'neutralizing antibodies' named entity 'peptidase' named entity 'administration' named entity 'intranasal' named entity 'vaccine' named entity 'serum' named entity 'infection' named entity 'humoral' named entity 'MERS-CoV' named entity 'intranasal' named entity 'neutralizing antibody' named entity 'dipeptidyl peptidase 4' named entity 'airway' named entity 'vaccines' named entity 'receptor' named entity 'virus' named entity 'DPP4' named entity 'Middle East respiratory syndrome coronavirus' named entity 'immune responses' named entity 'domain' named entity 'flow cytometer' named entity 'protein' named entity 'non-fat' named entity 'Vantaa' named entity 'molecular weight' named entity 'IFN-γ' named entity 'trypsin' named entity 'CD69' named entity 'DMEM' named entity 'fever' named entity 'IgA' named entity 'Ewha Woman's University' named entity 'plasmids' named entity 'DMEM' named entity 'pseudovirus' named entity 'Spike protein' named entity 'NaN3' named entity 'MERS-CoV' named entity 'secondary antibody' named entity 'IgA' named entity 'titer' named entity 'neutralizing antibodies' named entity 'adenoviruses' named entity 'RBD' named entity 'lung parenchyma' named entity 'vaccine' named entity 'genomic DNA' named entity 'GenBank' named entity 'adenovirus' named entity 'control group' named entity 'IFN-γ' named entity 'Perkin Elmer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software